Press release
Vancomycin Resistant Enterococcal Infections Pipeline Insight 2025: Novel Antibiotics and Innovative Therapies Aim to Overcome Rising Resistance | DelveInsight
DelveInsight's "Vancomycin Resistant Enterococcal (VRE) Infections - Pipeline Insight, 2025" highlights the evolving treatment landscape for one of the most pressing antimicrobial resistance (AMR) threats. VRE infections, caused by Enterococcus faecium and Enterococcus faecalis, are associated with bloodstream infections, urinary tract infections, and surgical site infections, particularly in immunocompromised patients. Limited treatment options and high mortality rates make VRE a significant clinical challenge.The pipeline features novel antibiotics with unique mechanisms of action, including lipoglycopeptides, oxazolidinones, and β-lactam/β-lactamase inhibitor combinations designed to circumvent resistance. Additionally, non-traditional approaches such as bacteriophage therapy, antimicrobial peptides, and microbiome-based interventions are under investigation to provide alternatives beyond conventional antibiotics.
Monoclonal antibodies targeting virulence factors and immune-modulating therapies are also being explored to enhance host defenses against VRE. Clinical studies are assessing key endpoints such as microbiological eradication, infection-related mortality, and recurrence prevention.
Global regulatory bodies are encouraging innovation through antimicrobial development incentives and fast-track designations, recognizing the urgent need for effective VRE therapies. With promising candidates in late-stage development, the therapeutic pipeline is advancing toward addressing a critical unmet need and reshaping the future of resistant infection management.
Interested in learning more about the current treatment landscape and the key drivers shaping the Vancomycin Resistant Enterococcal Infections pipeline? Click here: https://www.delveinsight.com/report-store/vancomycin-resistante-enterococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Vancomycin-Resistant Enterococcal Infections Pipeline Report
• DelveInsight's Vancomycin Resistant Enterococcal Infections pipeline analysis depicts a strong space with 4+ active players working to develop 4+ pipeline drugs for Vancomycin Resistant Enterococcal Infections treatment.
• The leading Vancomycin Resistant Enterococcal Infections companies include Rebiotix, Acurx Pharmaceuticals, Ovensa, Karveel Pharmaceuticals, iNtRON Biotechnology, and others are evaluating their lead assets to improve the Vancomycin Resistant Enterococcal Infections treatment landscape.
• Key Vancomycin Resistant Enterococcal Infections pipeline therapies in various stages of development include RBX2660, ACX-375C, SNP 021062, EFL 200, and others.
• In June 2025, DelveInsight's pipeline analysis highlighted that over 12 companies are advancing novel therapies for complicated urinary tract infections (cUTIs), including tebipenem pivoxil hydrobromide, which completed a pivotal Phase III trial showing non-inferiority to IV ertapenem. While this focuses on cUTIs broadly, tebipenem's spectrum includes enterococcal pathogens, including VRE.
Request a sample and discover the recent breakthroughs happening in the Vancomycin Resistant Enterococcal Infections pipeline landscape at https://www.delveinsight.com/report-store/vancomycin-resistante-enterococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Vancomycin-Resistant Enterococcal Infections Overview
Vancomycin-resistant enterococci (VRE) are strains of Enterococcus bacteria, most commonly E. faecalis and E. faecium, that have developed resistance to vancomycin, an antibiotic traditionally used to treat serious infections caused by gram-positive organisms. VRE infections typically occur in hospitalized or immunocompromised patients and can affect the urinary tract, bloodstream, wounds, or heart valves. Risk factors include prolonged hospital stays, prior antibiotic use, invasive devices like catheters, and weakened immune systems.
These infections pose significant clinical challenges due to limited treatment options and the potential for rapid spread in healthcare settings. Infection control measures, such as strict hand hygiene, patient isolation, and environmental cleaning, are essential to prevent transmission. Treatment often involves alternative antibiotics like linezolid, daptomycin, or tigecycline, depending on the infection site and susceptibility profile. Early detection, appropriate antibiotic stewardship, and adherence to infection control practices are key to managing and reducing the impact of VRE.
Find out more about Vancomycin Resistant Enterococcal Infections medication at https://www.delveinsight.com/report-store/vancomycin-resistante-enterococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Vancomycin-Resistant Enterococcal Infections Treatment Analysis: Drug Profile
RBX2660: Rebiotix
RBX2660, developed by Rebiotix Inc. (a Ferring Pharmaceuticals company), is an investigational therapy built on the company's proprietary Microbiota Restoration Therapy (MRTTM) drug platform. This platform is grounded in rigorous scientific research and stringent quality control processes to explore the therapeutic potential of human-derived microbiota. RBX2660 is currently in Phase I clinical trials for the treatment of vancomycin-resistant enterococcal (VRE) infections, aiming to assess its safety and potential to combat disease recurrence and progression through microbiota-based intervention.
Learn more about the novel and emerging Vancomycin Resistant Enterococcal Infections pipeline therapies at https://www.delveinsight.com/report-store/vancomycin-resistante-enterococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Vancomycin Resistant Enterococcal Infections Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Vancomycin-Resistant Enterococcal Infections Pipeline Report
• Coverage: Global
• Key Vancomycin Resistant Enterococcal Infections Companies: Rebiotix, Acurx Pharmaceuticals, Ovensa, Karveel Pharmaceuticals, iNtRON Biotechnology, and others.
• Key Vancomycin Resistant Enterococcal Infections Pipeline Therapies: RBX2660, ACX-375C, SNP 021062, EFL 200, and others.
To dive deep into rich insights for drugs used for Vancomycin Resistant Enterococcal Infections treatment, visit: https://www.delveinsight.com/report-store/vancomycin-resistante-enterococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Vancomycin-Resistant Enterococcal Infections Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Vancomycin-Resistant Enterococcal Infections Pipeline Therapeutics
6. Vancomycin-Resistant Enterococcal Infections Pipeline: Late-Stage Products (Phase III)
7. Vancomycin-Resistant Enterococcal Infections Pipeline: Mid-Stage Products (Phase II)
8. Vancomycin-Resistant Enterococcal Infections Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Vancomycin Resistant Enterococcal Infections Pipeline Insight 2025: Novel Antibiotics and Innovative Therapies Aim to Overcome Rising Resistance | DelveInsight here
News-ID: 4172072 • Views: …
More Releases from DelveInsight

Type 2 Diabetes Pipeline Insight 2025: Next-Gen Incretins, Gene Therapies, and M …
DelveInsight's "Type 2 Diabetes - Pipeline Insight, 2025" explores the evolving pipeline for type 2 diabetes (T2D), a chronic disorder marked by insulin resistance and progressive β-cell dysfunction. Despite widely used options like metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin, the global burden of T2D continues to rise, creating demand for therapies that go beyond glucose control to address weight, cardiovascular risk, and long-term disease modification.
The pipeline is advancing…

Wet Age-Related Macular Degeneration Pipeline Insight 2025: Over 60+ Companies A …
DelveInsight's "Wet-AMD - Pipeline Insight, 2025" maps a fast-moving landscape for neovascular (wet) age-related macular degeneration, a leading cause of vision loss driven by choroidal neovascularization and exudation. Today's standard of care relies on frequent intravitreal anti-VEGF injections, which are highly effective but create a heavy treatment burden and adherence challenges.
The pipeline is shifting toward durability and disease modification. Next-gen biologics (long-acting antibodies, bispecifics, and high-affinity fragments), small-molecule TKIs in…

Pulmonary Embolism Pipeline Insight 2025: Novel Anticoagulants, Thrombolytics, a …
DelveInsight's "Pulmonary Embolism - Pipeline Insight, 2025" explores the advancing treatment landscape for pulmonary embolism, a life-threatening condition resulting from obstruction of the pulmonary arteries, most often due to venous thromboembolism. Current management primarily relies on anticoagulation with heparins, vitamin K antagonists, or direct oral anticoagulants, and in severe cases, systemic thrombolysis or catheter-directed interventions. While these approaches improve survival, they are limited by bleeding risks, suboptimal clot resolution, and…

Immune Thrombocytopenia Clinical Trials 2025: Advancing TPO-R Agonists, FcRn Blo …
DelveInsight's "Immune Thrombocytopenia (ITP) - Pipeline Insight, 2025" highlights the rapidly evolving therapeutic landscape for ITP, an autoimmune bleeding disorder characterized by accelerated platelet destruction and impaired platelet production. Current treatments, such as corticosteroids, intravenous immunoglobulin (IVIG), rituximab, and thrombopoietin receptor (TPO-R) agonists like eltrombopag and romiplostim, provide effective short-term control for many patients, but relapses, refractoriness, and treatment-related toxicity remain significant challenges.
The pipeline is shifting toward therapies that deliver…
More Releases for Vancomycin
Vancomycin Hydrochloride for Injection Market Size And Global Industry Forecast …
" The global market for Vancomycin Hydrochloride for Injection is valued at approximately $860 million in 2024, with a projected increase to around $1.4 billion by the end of 2034. This represents a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period from 2025 to 2034. "
Exactitude Consultancy., Ltd. released a research report titled "Vancomycin Hydrochloride for Injection Market". This report covers the global Vancomycin Hydrochloride for Injection…
Vancomycin Hydrochloride for Injection Market Size And Global Industry Forecast …
" The global market for Vancomycin Hydrochloride for Injection is valued at approximately $860 million in 2024, with a projected increase to around $1.4 billion by the end of 2034. This represents a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period from 2025 to 2034. "
Exactitude Consultancy., Ltd. released a research report titled "Vancomycin Hydrochloride for Injection Market". This report covers the global Vancomycin Hydrochloride for Injection…
Global Vancomycin Market Analysis 2025-2030: Growth Drivers, Challenges, And Opp …
The Vancomycin Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Vancomycin Market Size Expected to Be by 2034?
The vancomycin market has expanded rapidly in recent years. It will grow from $0.82 billion in 2024 to $0.92 billion in 2025 at a…
Vancomycin Hydrochloride Manufacturing Project Cost: Industry Trends and Raw Mat …
Setting up a vancomycin hydrochloride plant facility necessitates a detailed market analysis alongside granular insights into various operational aspects, including unit processes, raw material procurement, utility provisions, infrastructure setup, machinery and technology specifications, workforce planning, logistics, and financial considerations.
IMARC Group's report titled "Vancomycin Hydrochloride Manufacturing Plant Project Report 2025: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" offers a comprehensive guide for establishing a vancomycin hydrochloride…
Impact Of Rising Infectious Disease Prevalence On The Vancomycin Market Driver: …
What Are the Projected Growth and Market Size Trends for the Vancomycin Market?
There has been a swift expansion in the size of the vancomycin market in the past few years. The market, which was valued at $0.82 billion in 2024, is projected to reach $0.92 billion by 2025, boasting a compound annual growth rate (CAGR) of 11.5%. The significant growth experienced in the historical period is credited to factors…
Vancomycin Market to see Rapid Growth by 2029
Vancomycin Market size was valued at USD billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of % from 2024 to 2030. The Vancomycin market is witnessing significant growth, driven by its critical role in treating severe bacterial infections. As a potent antibiotic, Vancomycin is widely used to combat infections caused by Gram-positive bacteria, including MRSA (Methicillin-resistant Staphylococcus aureus). With the increasing prevalence of…